Core Insights - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, reporting recent accomplishments and financial results for Q2 2025 [1][10] Recent Accomplishments - The company is confident in its late-stage rare disease pipeline, with key milestones expected, including top-line results from a Phase 2a clinical trial for mild-to-moderate psoriasis with SGX302 by year-end [2] - Successful completion of a Phase 2a proof of concept study for SGX945 in Behçet's Disease, demonstrating biological efficacy [2][9] - Ongoing clinical updates for the extended HyBryte™ treatment for early-stage cutaneous T-cell lymphoma (CTCL) and plans for a Phase 3 study [2] Financial Results - No revenue was reported for Q2 2025, consistent with minimal revenue in Q2 2024 [4] - Net loss for Q2 2025 was $2.7 million, or ($0.82) per share, compared to a net loss of $1.6 million, or ($1.31) per share in Q2 2024, primarily due to increased operating expenses [5] - Research and development expenses rose to $1.7 million in Q2 2025 from $0.5 million in Q2 2024, driven by costs related to clinical trials [6] - General and administrative expenses decreased to $1.1 million in Q2 2025 from $1.2 million in Q2 2024 [7] - Cash position as of June 30, 2025, was approximately $5.1 million, excluding $1.4 million received via the ATM facility on July 1, 2025 [7] Strategic Focus - The company is evaluating strategic options, including partnerships, mergers, acquisitions, government grants, and financing opportunities to advance its late-stage pipeline [2]

Core Insights - Soligenix, Inc. is focused on developing and commercializing products for rare diseases with unmet medical needs, reporting recent accomplishments and financial results for Q1 2025 [1][9] Recent Accomplishments - The company anticipates significant milestones, including top-line results in 2026 from a Phase 3 study of HyBryte™ for early-stage cutaneous T-cell lymphoma and results from Phase 2 studies of SGX945 in Behçet's disease and SGX302 in psoriasis in the second half of 2025 [2] Financial Results - For the quarter ended March 31, 2025, Soligenix reported no revenue, a decrease from $0.1 million in the same quarter of 2024, primarily due to a reduction in revenue from a zero-margin grant for HyBryte™ [5] - The net loss for Q1 2025 was $3.2 million, or ($1.06) per share, compared to a net loss of $1.9 million, or ($2.91) per share, in Q1 2024, attributed to increased operating expenses and a decrease in other income [6] - Research and development expenses rose to $2.2 million in Q1 2025 from $1.1 million in Q1 2024, driven by costs related to ongoing clinical trials [7] - General and administrative expenses increased to $1.1 million in Q1 2025 from $1.0 million in Q1 2024, mainly due to higher professional expenses and taxes [8] Cash Position - As of March 31, 2025, the company's cash position was approximately $7.3 million, which is expected to provide sufficient operating runway through December 2025 [3][8]

Core Viewpoint - Soligenix, Inc. is focused on advancing its clinical programs and achieving significant development milestones, particularly in the treatment of rare diseases with unmet medical needs, while managing its financial resources effectively [2][9]. Recent Accomplishments - The company has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ in early-stage cutaneous T-cell lymphoma (CTCL) and has reported positive interim results from an open-label study of HyBryte™ [7][9]. - Formation of a European Medical Advisory Board to provide strategic guidance for the ongoing clinical studies [7]. Financial Results - For the year ended December 31, 2024, Soligenix reported revenues of $0.1 million, a decrease from $0.8 million in the previous year, primarily due to timing issues with government grant funding [4]. - The net loss for the year was $8.3 million, or ($4.98) per share, compared to a net loss of $6.1 million, or ($12.66) per share, in the prior year, influenced by a reverse stock split and increased research and development expenses [5][6]. - Research and development expenses rose to $5.2 million from $3.3 million, driven by costs related to new clinical trials [6]. Cash Position - As of December 31, 2024, the company had approximately $7.8 million in cash, which is expected to support operations through 2025 while exploring various strategic options for funding [2][8].